UK MedTech Renalytix is to appeal against a delisting from the Nasdaq exchange. Renalytix, which is targeting kidney disease, is dual-listed in New York and London. In December it was notified by Nasdaq that it was at risk of being delisted in the United States after failing to meet a minimum bid price over 30 … Continue reading UK MedTech to appeal delisting from Nasdaq